Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Recruiting 2Not yet recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 27Head & Neck 6Thoracic 4Gynecologic 4Genitourinary 3Breast 3

Conditions

Prostatic Neoplasms 334Carcinoma, Renal Cell 112Urinary Bladder Neoplasms 95Breast Neoplasms 55Carcinoma, Transitional Cell 52Colorectal Neoplasms 43Carcinoma, Non-Small-Cell Lung 42Melanoma 41Ovarian Neoplasms 39Kidney Neoplasms 39Neoplasms 38Neoplasm Metastasis 31Lung Neoplasms 28Sarcoma 26Non-Muscle Invasive Bladder Neoplasms 26Uterine Cervical Neoplasms 25Pancreatic Neoplasms 24Endometrial Neoplasms 23Stomach Neoplasms 22Wilms Tumor 19Squamous Cell Carcinoma of Head and Neck 19Carcinoma, Hepatocellular 19Esophageal Neoplasms 18Adenocarcinoma 18Triple Negative Breast Neoplasms 17Head and Neck Neoplasms 17Small Cell Lung Carcinoma 15Thyroid Neoplasms 14Metastatic Castration-resistant Prostate Cancer 14Neuroblastoma 13

Interventions

pembrolizumab 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Esophageal Squamous Cell Carcinoma × Genitourinary × 30 days × Clear all
NCT07217171 2026-06-03

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas

EvolveImmune United, Inc

Phase 1 Recruiting
160 enrolled
GastrointestinalGenitourinary

Esophageal Squamous Cell Carcinoma, Anus Neoplasms, Urinary Bladder Neoplasms

NCT07623642 2026-06-03

A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.

GV20 Therapeutics

Phase 2 Not yet recruiting
227 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Gallbladder Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04389632 2026-05-11

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Seagen Inc.

Phase 1 Recruiting
1,006 enrolled
GastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡